



Danielle D. Knight, MD

Danielle Knight, MD joined the cancer care team of Northwest Georgia Oncology Centers, P.C. (NGOC) after caring for patients in the Bassett Healthcare system Cooperstown NY. She received her medical degree from State University of New York Downstate Medical Center Doctor of Medicine in Brooklyn NY and her internship and residency at Montefiore Medical Center the University Hospital for the Albert Einstein College of Medicine.

Dr. Knight provides patient-centered cancer care at NGOC's **Carrollton Cancer Center**.

Education	<p>State University of New York Downstate Medical Center Doctor of Medicine Brooklyn, NY May 2004 Honors: Yudowsky Honor Scholarship, Shalita Marmour Scholarship, SUNY Brooklyn Health Science Center Scholar</p> <p>Cornell University Ithaca, NY May 2000 Bachelor of Science in Biology, Cum Laude Honors: Cornell University Office of Minority Affairs Committee on Special Education Projects Academic Excellence Award, SUNY Empire State Minority Honors Scholarship, The Hundred Year Association of New York College Scholar Award, Emigrant Savings Bank Community Scholarship Award, Governor's Committee on Scholastic Achievement Award</p>
Internship and Residency	<p>Montefiore Medical Center the University Hospital for the Albert Einstein College of Medicine Bronx, NY 2004-2007</p> <p>Internal Medicine Resident The medical center is a major center. As a senior resident, responsibilities included running hospital codes, assigning patients to the Medicine Service, and supervising other residents and medical students.</p>
Fellowship	<p>New York University Medical Center Hematology and Medical Oncology Fellow 2007-2010 - New York, NY The medical center is a major center consisting of 3 different large hospitals. As a fellow, had major role in decision making for patient care. Supervised residents and medical students</p>
Board Certification & Medical Licensure	<p>American Board of Internal Medicine- Hematology, since 2010 American Board of Internal Medicine- Medical Oncology, since 2010 Licensed in New Jersey, since 2010 American Board of Internal Medicine- Internal Medicine, since 2007 Licensed in New York, since 2007</p>
Professional Societies	<p>American Society of Clinical Oncology, 2007-present American Society of Hematology, 2007-present American College of Physicians, 2006-present National Medical Association, 2004-present Medical Society of the State of New York, 2000-present American Medical Association, 2000-present</p>
Teaching Experience and Honors	<p>New York University Medical Center Hematology/Oncology Fellow Gave several lectures to the residents and interns on different topics in Hematology and Oncology, including: Her2+ breast cancer, stage IV colon cancer, non small cell lung cancer,</p> <p style="text-align: right;">New York, NY 2007-2010</p>

myelodysplasia, acute myeloid leukemia, hairy cell leukemia, transfusion reactions, and the myeloproliferative disorders.

State University of New York Downstate Medical Center Brooklyn, NY
 Medical Student, Tutor, Department of Academic Development 2001-2002
 Instructed first year medical students in anatomy, biochemistry, genetics, and physiology, including lectures and review sessions.

State University of New York Downstate Medical Center Brooklyn, NY
 Medical Student, Tutor/Program Coordinator, Department of 2001
 Minority Affairs
 Instructed pre-matriculating minority students during a summer program in anatomy, biochemistry, genetics, and physiology, including lectures and review sessions.

Honors

Introduction to Bedside Diagnosis Outstanding Instructor 2007-2008

Research

New York University Medical Center
 New York, NY
 Clinical Research Assistant, Department of Medical Oncology 2009-2010
 Recruited patients for the trial "A Study to evaluate 3.0 Tesla Magnetic Resonance Imaging (MRI) of the breasts in high risk women." Women with high risk for breast cancer were evaluated with the 3.0 Tesla MRI to explore the possible added benefit of 3.0 Tesla MRI in evaluating suspicious lesions seen on mammography and/or ultrasound.

New York University Medical Center
 New York, NY
 Clinical Research Assistant, Department of Medical Oncology 2009-2010
 Organized and analyzed data and also played a large role in writing the final manuscript for the paper entitled "A Phase I Trial of Dose Dense (Biweekly) Carboplatin Combined with Paclitaxel and Pegfilgrastim: A Feasibility Study in Patients with Untreated Stage III and IV Ovarian, Tubal or Primary Peritoneal Cancer; A Gynecologic Oncology Group Study." In this study, women with untreated stage III or IV carcinosarcoma, epithelial ovarian, fallopian, tube, or primary peritoneal cancer were treated with carboplatin and paclitaxel and pegfilgrastim every 2 weeks. Participants were monitored for toxicity and efficacy.

New York University Medical Center
 New York, NY
 Clinical Research Assistant, Department of Medical Oncology 2009
 First author for abstract and poster presenter at the 2009 San Antonio Breast Cancer Symposium for the study "A Phase 1b Study to Assess the Safety, Feasibility, Pharmacokinetics, and Activity of PTC299 Monotherapy or Combination Therapy with Hormonal Agents in Patients with Metastatic Breast Cancer." Patients received PTC299 monotherapy in repeated 6 weeks cycles each made up of a 4 weeks course of daily PTC299 given twice a day, followed by a 2 week washout period. Different cohorts of patients got higher doses of PTC299 until disease progression or unacceptable toxicity.

New York University Medical Center
 New York, NY
 Clinical Research Assistant, Department of Medical Oncology 2009
 First author for abstract and poster presenter at the June 2009 Western Association of Gynecologic Oncology's Annual Meeting for the study "Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study." In the study women with newly diagnosed stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal adenocarcinoma who were not candidates for initial surgical treatment, were

given neoadjuvant chemotherapy, then had debulking surgery. Tissue samples from the operating room were correlated with progression free survival.

Montefiore Medical Center the University Hospital for the Albert Bx, NY
Einstein College of Medicine 2005
Research Assistant, Department of Oncology

Quality of life of cancer patients was assessed in a study entitled "Quality of life of patients in a phase I clinical trial with weekly Irinotecan and oral Capecitabine, both administered for two weeks of a three week cycle, in patients with advanced solid malignancies." Patients given questionnaire related to 6 components of quality of life. Questionnaire given before beginning chemotherapy and after every 2 cycles (6 weeks) for duration of chemotherapy. Responses analyzed for significant changes after chemotherapy was started compared to before chemotherapy started.

Cornell University Ithaca, NY
Laboratory Assistant, Department of Biology 1996-2000
Laboratory Assistant, Department of Biology, Cornell

Requirements for sequences surrounding editing sites in plants was studied, using DNA transformation and sequence analysis. Transgenic analysis was performed by analysis of editing sites of tobacco plant gene (gene that encodes one of the beta subunits of a chloroplast specific DNA dependent RNA polymerase. It was found that alteration of the 20 nucleotide 5' to the editing site inhibits RNA editing.

PUBLICATIONS

Tiersten A, Sill M, Knight D, Muggia F, Garcia A, Fracasso P, Swensen R, Warshal D, Mannel R. A Phase I Trial of Dose Dense (Biweekly) Carboplatin Combined with Paclitaxel and Pegfilgrastim: A Feasibility Study in Patients with Untreated Stage III and IV Ovarian, Tubal or Primary Peritoneal Cancer; A Gynecologic Oncology Group Study. *Gynecologic Oncology* 2010; 118: 303-307.

Knight D, Tiersten A, Miao H, Llorente M, Elfring G, Novik Y, Speyer J, Volm M, Miller L. PTC299, a Novel Regulator of Tumor VEGF Expression, is Well Tolerated and Achieves Target Plasma Concentrations: Dose-ranging Results of a Phase 1b Study in Women with Metastatic Breast Cancer. 32nd Annual San Antonio Breast Cancer Symposium Abstract 6092.

Knight D, Moon J, Smith H, Wilczynski SP, Robinson WR, Markman M, Alberts DS, Tiersten AD. Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study. 2009 Joint WAGO/GOC Meeting. Vancouver, BC June 24-27 2009.